Lord, Abbett & Co’s Travere Therapeutics TVTX Stock Holding History

Lord, Abbett & Co’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-425,000	Closed	-$503K	–	584
2025 Q1	$503K	Buy	+425,000	New	+$8.63M	﹤0.01%	530

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lord, Abbett & Co's TVTX Position: Q1 2026 in Review

Lord, Abbett & Co sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 135,822 shares — an estimated $5.19M sold.

Lord, Abbett & Co first reported a position in TVTX in Q2 2015 and held it in 6 quarters. The position peaked at $10.1M in Q1 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Lord, Abbett & Co reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Lord, Abbett & Co sold 135,822 Travere Therapeutics shares in Q1 2026, an estimated $5.19M.
Lord, Abbett & Co first reported a position in Travere Therapeutics in Q2 2015 and held it in 6 quarters.
Lord, Abbett & Co's Travere Therapeutics position peaked at $10.1M in Q1 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.